AzTrials
AzTrials

Hepatitis CNCT04618679

Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.

An observational study of Hepatitis C, run by National Taiwan University Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function. The decreased uptake of 18F-FDOPA in the posterior putamen is demonstrated in the early course of PD, and could differentiate early PD from healthy controls. Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
Hepatitis C
How many people
100 participants
Where
1 siteTaiwan
Study dates
2 Nov 2020to 30 Jun 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Outpatient department of hospital

Adults (older than 20-year-old) with HCV infection and agree to accept 18F-FDOPA PET examination.

Trial locations and contacts

1 site in 1 country.

Chia-Ju Liu, MD contact

886972655524

Y05955@ms1.ylh.gov.tw

Kai-Chieh Chang, MD contact

886972652523

b94401022@ntu.edu.tw

Taiwan1 site
  • National Taiwan University Hospital

    Douliu, Yunlin County, 640

    Chia-Ju Liu, MD, 886972655524, Y05955@ms1.ylh.gov.tw

Other trials in Taiwan

About this study

-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function. The decreased uptake of 18F-FDOPA in the posterior putamen is demonstrated in the early course of PD, and could differentiate early PD from healthy controls. The objective of this study is to investigate the evidence of presynaptic dopaminergic neuronal dysfunction in the preclinical stage of PD, which may be associated with HCV infection.

Read the detailed description

Parkinson's disease (PD) is the second-most neurodegenerative disease in Taiwan. It is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The estimated incidence of PD ranging from 10-18 per 100,000 person-years with a tread of increasing number over past decades. Although the exact mechanisms of PD have not yet fully clear, many pathological process have shown to be involved in the pathogenesis like abnormal alpha-synuclein, activation of microglia and astrocyte, mitochondrial dysfunction, oxidative stress, and so on.

Several characteristics have been considered to increase the risk of having PD. Epidemiologic studies have suggested that patients with HCV infection might have higher risk of PD. It is common that patients with chronic HCV infection manifest with central nervous system manifestations, such as depression, fatigue, and cognitive dysfunction. A previous epidemiologic study in Taiwan with a total of 62,276 subjects showed that there is significant correlation between PD and hepatitic C virus (HCV) infection. In the study, the crude odds ratio for having PD was 1.94 for HCV patients.

HCV is positive-stranded RNA virus of Flaviviridae family. Flaviviridae family has many viruses demonstrating neurotropic character and may be associated with encephalopathy. Decreased monoamine transporter binding activity had also been found in HCV infected patients who had symptoms of chronic fatigue and cognitive impairment. HCV can cross blood-brain barrier and has the ability to replicate in the central nervous system. Animal study has shown that HCV infection may up-regulate the inflammatory cytokines, such as sICAM-1, LIX, and RANTES, in the rat midbrain neuron-glia coculture and induced dopaminergic neuronal toxicity. The elevation of choline/creatine ratio on proton magnetic-resonance spectroscopy is also indicative of inflammatory status of brain in patients with chronic HCV infection. it is possible that the direct infection of HCV into the brain induce inflammatory status by microglia/macrophages and contribute to subsequent neurodegeneration. Chronic HCV infection is also associated with systemic cytokine activation including interferon-α and tumor necrosis factor α, which may also affect the neuronal function. It has been reported that the viral eradication on the patients infected by HCV had change of neurocognitive function.

6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) is an analog of L-dihydroxyphenylalanine (L-DOPA), which is the precursor of dopamine. L-DOPA is carried into the brain through neutral amino acid transport system and converted to domapine by aromatic L-amino acid decarboxylase (AADC) in dopaminergic neurons. Use 18F-FDOPA as a tracer of positron emission tomography (PET) imaging, the dopamine synthesis rate and presynaptic dopaminergic neuronal function can be reflected by the uptake of 18F-FDOPA in dopaminergic neurons. The decline of 18F-FDOPA is indicative of dopaminergic neurons dysfunction and can be used as imaging marker of the severity of PD. The posterior putamen receives the dopaminergic projections from the ventrolateral part of the substantia nigra and is affected earliest in the disease course of PD. 18F-FDOPA has been shown its capacity in differentiating early PD and healthy controls in previous study with lower metabolism in the dorsal putamen even in the early course of PD.

In this project, 18F-FDOPA PET is used as an imaging marker of striatal dopaminergic dysfunction in patients with HCV infection. We will try to detect the subclinical and preclinical stages of parkinsonism for these patients.

Conditions
Hepatitis C
Keywords
HBV,Parkinson's disease,18F-FDOPA PET
Medical subject headings
Hepatitis C

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04618679
Study groupRoleWhat they receive
18F-FDOPA PETPatients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease.

    To evaluate the uptake of 18F-FDOPA in the basal ganglia of patients with HCV infection. Use 18F-FDOPA PET as an imaging marker to diagnosis preclincal Parkinson's disease in patients with HCV infection.

    Measured: 2 weeks

Secondary outcomes (1)
  1. Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease.

    To compare the findings of 18F-FDOPA PET with the disease status of HCV infection and investigate possible correlation between the severity of Parkinson's disease and HCV infection status.

    Measured: 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Nov 2020
  2. Study start2 Nov 2020 (estimated)
  3. Primary completion30 Jun 2021 (estimated)
  4. Study completion30 Jun 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04618679
Sponsor's protocol ID
201912133MIND
Status last verified
Oct 2020
First submitted
1 Nov 2020
Last updated
6 Nov 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Hepatitis C, run by National Taiwan University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Chia-Ju Liu, MD (886972655524, Y05955@ms1.ylh.gov.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease. (time frame: 2 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in